Form 4: Syros Pharmaceuticals Director Deborah Dunsire Reports Stock Option and RSU Grants

Director Deborah Dunsire reports the acquisition of stock options and restricted stock units (RSUs) in Syros Pharmaceuticals.

Summary

• On June 5, 2024, Deborah Dunsire, a director of Syros Pharmaceuticals, reported the acquisition of stock options and restricted stock units (RSUs).
• Dunsire acquired options to purchase 6,000 shares of common stock at an exercise price of $5.30.
• These options vest as to 50% six months from the grant date, with the remainder vesting in equal monthly installments over the following six months, contingent upon continued service as a director.
• Additionally, Dunsire acquired 4,000 RSUs, each representing the right to receive one share of Syros Pharmaceuticals common stock.
• These RSUs will vest on the earlier of the first anniversary of the grant date or the date of the company's next Annual Meeting of Stockholders, also contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard compensation practices for a company director. The grants align director interests with shareholders, which is generally viewed positively, but it's a routine disclosure.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of compensation for directors in publicly traded companies, aligning their interests with shareholders.
• Vesting schedules are typical and designed to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the grants positively as they align the director's interests with the company's performance.
• The grants incentivize the director to contribute to the company's long-term success.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Deborah Dunsire, Stock Options, Restricted Stock Units, RSUs, Form 4, Beneficial Ownership